CSL Behring LLC, of King of Prussia, Pa., announced the publication in the New England Journal of Medicine of results from the Compact study, a pivotal phase III trial evaluating the safety and efficacy of CSL830 (C1-esterase inhibitor [C1-INH] human replacement therapy) for the prevention of hereditary angioedema (HAE) attacks.